Literature DB >> 21789158

Bevacizumab in metastatic breast cancer: when may it be used?

Shari B Goldfarb1, Clifford Hudis, Maura N Dickler.   

Abstract

Tumor angiogenesis, which is necessary for breast cancer growth, invasion and metastases, is regulated by pro-angiogenic factors such as vascular endothelial growth factor (VEGF). Bevacizumab is a recombinant humanized monoclonal antibody that targets VEGF. The addition of bevacizumab to chemotherapy has improved progression-free survival in the first- and second-line treatment of patients with advanced-stage breast cancer. In this article we review the clinical trials testing the utility of bevacizumab for the treatment of metastatic disease.

Entities:  

Keywords:  bevacizumab; breast cancer; progression-free survival; vascular endothelial growth factor

Year:  2011        PMID： 21789158      PMCID： PMC3126041          DOI： 10.1177/1758834010397627

Source DB:  PubMed          Journal:  Ther Adv Med Oncol        ISSN： 1758-8340            Impact factor:   8.168


  26 in total

1.  Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment.

Authors:  B Linderholm; K Grankvist; N Wilking; M Johansson; B Tavelin; R Henriksson
Journal:  J Clin Oncol       Date:  2000-04       Impact factor: 44.544

2.  Chromatin immunoprecipitation analysis of gene expression in the rat uterus in vivo: estrogen-induced recruitment of both estrogen receptor alpha and hypoxia-inducible factor 1 to the vascular endothelial growth factor promoter.

Authors:  Armina A Kazi; Jenny M Jones; Robert D Koos
Journal:  Mol Endocrinol       Date:  2005-03-17

3.  High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer.

Authors:  J A Foekens; H A Peters; N Grebenchtchikov; M P Look; M E Meijer-van Gelder; A Geurts-Moespot; T H van der Kwast; C G Sweep; J G Klijn
Journal:  Cancer Res       Date:  2001-07-15       Impact factor: 12.701

4.  Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol.

Authors:  N Klauber; S Parangi; E Flynn; E Hamel; R J D'Amato
Journal:  Cancer Res       Date:  1997-01-01       Impact factor: 12.701

5.  Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.

Authors:  David W Miles; Arlene Chan; Luc Y Dirix; Javier Cortés; Xavier Pivot; Piotr Tomczak; Thierry Delozier; Joo Hyuk Sohn; Louise Provencher; Fabio Puglisi; Nadia Harbeck; Guenther G Steger; Andreas Schneeweiss; Andrew M Wardley; Andreas Chlistalla; Gilles Romieu
Journal:  J Clin Oncol       Date:  2010-05-24       Impact factor: 44.544

6.  RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.

Authors:  Adam M Brufsky; Sara Hurvitz; Edith Perez; Raji Swamy; Vicente Valero; Vincent O'Neill; Hope S Rugo
Journal:  J Clin Oncol       Date:  2011-10-11       Impact factor: 44.544

7.  Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor.

Authors:  R K Jain; N Safabakhsh; A Sckell; Y Chen; P Jiang; L Benjamin; F Yuan; E Keshet
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-01       Impact factor: 11.205

8.  Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.

Authors:  Kathy Miller; Molin Wang; Julie Gralow; Maura Dickler; Melody Cobleigh; Edith A Perez; Tamara Shenkier; David Cella; Nancy E Davidson
Journal:  N Engl J Med       Date:  2007-12-27       Impact factor: 91.245

9.  The microtubule-affecting drug paclitaxel has antiangiogenic activity.

Authors:  D Belotti; V Vergani; T Drudis; P Borsotti; M R Pitelli; G Viale; R Giavazzi; G Taraboletti
Journal:  Clin Cancer Res       Date:  1996-11       Impact factor: 12.531

10.  A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer.

Authors:  Melody A Cobleigh; Virginia K Langmuir; George W Sledge; Kathy D Miller; Latrice Haney; William F Novotny; James D Reimann; Amy Vassel
Journal:  Semin Oncol       Date:  2003-10       Impact factor: 4.929
View more
  8 in total

1.  Antiangiogenic therapy of breast cancer: how did we get here?: the road not taken.

Authors:  E Alba
Journal:  Clin Transl Oncol       Date:  2011-11       Impact factor: 3.405

2.  A new immunotherapy schedule in addition to first-line hormone therapy for metastatic breast cancer patients in a state of clinical benefit during hormone therapy.

Authors:  Andrea Nicolini; Giuseppe Rossi; Paola Ferrari; Riccardo Morganti; Angelo Carpi
Journal:  J Mol Med (Berl)       Date:  2020-01-29       Impact factor: 4.599

3.  In vitro the behaviors of metastasis with suppression of VEGF in human bone metastatic LNCaP-derivative C4-2B prostate cancer cell line.

Authors:  Lei Yang; Shuo You; Vikas Kumar; Chaoyue Zhang; Ya Cao
Journal:  J Exp Clin Cancer Res       Date:  2012-05-01

4.  Inhibition of VEGF and Angiopoietin-2 to Reduce Brain Metastases of Breast Cancer Burden.

Authors:  Kaci A Bohn; Chris E Adkins; Mohamed I Nounou; Paul R Lockman
Journal:  Front Pharmacol       Date:  2017-04-11       Impact factor: 5.810

5.  Zebrafish xenografts as a fast screening platform for bevacizumab cancer therapy.

Authors:  Cátia Rebelo de Almeida; Raquel Valente Mendes; Anna Pezzarossa; Joaquim Gago; Carlos Carvalho; António Alves; Vitor Nunes; Maria José Brito; Maria João Cardoso; Joana Ribeiro; Fátima Cardoso; Miguel Godinho Ferreira; Rita Fior
Journal:  Commun Biol       Date:  2020-06-10

6.  Non-conventional and Investigational PET Radiotracers for Breast Cancer: A Systematic Review.

Authors:  Michele Balma; Virginia Liberini; Manuela Racca; Riccardo Laudicella; Matteo Bauckneht; Ambra Buschiazzo; Daniele Giovanni Nicolotti; Simona Peano; Andrea Bianchi; Giovanni Albano; Natale Quartuccio; Ronan Abgral; Silvia Daniela Morbelli; Calogero D'Alessandria; Enzo Terreno; Martin William Huellner; Alberto Papaleo; Désirée Deandreis
Journal:  Front Med (Lausanne)       Date:  2022-04-12

7.  A Phase Ib multicenter, dose-escalation study of the polyamine analogue PG-11047 in combination with gemcitabine, docetaxel, bevacizumab, erlotinib, cisplatin, 5-fluorouracil, or sunitinib in patients with advanced solid tumors or lymphoma.

Authors:  Tracy Murray Stewart; Daniel Von Hoff; Michael Fitzgerald; Laurence J Marton; Carlos H Roberto Becerra; Thomas E Boyd; Paul R Conkling; Lawrence E Garbo; Robert M Jotte; Donald A Richards; David A Smith; Joe J Stephenson; Nicholas J Vogelzang; Hillary H Wu; Robert A Casero
Journal:  Cancer Chemother Pharmacol       Date:  2020-11-19       Impact factor: 3.333

8.  Anti-angiogenesis therapy and gap junction inhibition reduce MDA-MB-231 breast cancer cell invasion and metastasis in vitro and in vivo.

Authors:  Kazem Zibara; Zahraa Awada; Leila Dib; Jamal El-Saghir; Sara Al-Ghadban; Aida Ibrik; Nabil El-Zein; Marwan El-Sabban
Journal:  Sci Rep       Date:  2015-07-28       Impact factor: 4.379
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.